A traditional Chinese medicine composition for treating diffuse pulmonary fibrosis and its application

Abstract

The invention relates to a diffuse interstitial pulmonary fibrosis treating Chinese herb formula. The diffuse interstitial pulmonary fibrosis treating Chinese herb formula can effectively solve the problem of drug use for treatment of diffuse interstitial pulmonary fibrosis. The diffuse interstitial pulmonary fibrosis treating Chinese herb formula is composed of 1-50 mg of ginsenoside Re, 10-100 mg of icariin, 0.5-10 mg of nobiletin, 1-10 mg of peimine, 2-8 mg of paeoniflorin and 2-10 mg of isoliquirtigenin, and the content of all the components is not lower than 98%. Through repeated verification, the diffuse interstitial pulmonary fibrosis treating Chinese herb formula can achieve good therapeutic effects on pulmonary fibrosis, alleviate symptoms, enhance pulmonary functionality, improvealveolitis and pulmonary fibrosis and reduce lung tissue collagen deposition, thereby being fit for long-term application to treating diffuse interstitial pulmonary fibrosis. The diffuse interstitialpulmonary fibrosis treating Chinese herb formula is reasonable in composition, scientific in method, high in innovation, obvious in curative effects and significant in economic and social benefits.

Description

technical field [0001] The invention relates to the field of medicine, and relates to a traditional Chinese medicine composition for treating diffuse pulmonary interstitial fibrosis and an application thereof. Background technique [0002] Diffuse pulmonary interstitial fibrosis is a group of diffuse pulmonary diseases that involve the pulmonary interstitium and alveolar spaces, leading to the loss of alveolar-capillary functional units. . The etiology of the disease is complex, which may be related to dust, harmful smoke, infection, drugs, etc. The clinical manifestations are progressively aggravated dyspnea, restrictive ventilatory disorder with reduced diffusion function, and eventually respiratory failure. Among them, the most representative one is idiopathic pulmonary fibrosis (Idiopathic Pulmonary Fibrosis, IPF) and the like. [0003] IPF is the most common interstitial lung disease in clinical practice, and it is more common in men than women in clinical practice, a...

AI Technical Summary

Problems solved by technology

In 2015, the American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Society (ALAT) revised the 2011 version of IPF guidelines, pointing out that pirfenidone is the recommended drug , but its adverse reactions are extensive, and some patients still cannot tolerate certain adverse reactions even when the treatment benefit is assessed by forced vital capacity (FVC)

In addition, the cost of pirfenidone treatment is relatively high, and it is difficult to promote clinically.

Images